Design of a phase 2b randomized clinical trial (ENDEAVOR) to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in HF with preserved and mildly reduced EF
21 May 2023 (15:10 - 15:20)
Organised by: 
About the speaker
Karolinska University Hospital, Stockholm (Sweden)
2 More presentations in this session
Doctor M. Kim (Seoul, KR)
Access the full session
The Event
Heart Failure 2023
21 May 2023
15:10 CET
You may be interested in
Congress Presentation
Congress Presentation
Congress Session
